12 completed, 4 unknown, 1 active not recruiting, 1 not yet recruiting. 19 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 12, Unknown 4, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Unknown 1 |
Follow Diabetes Type 2: new trials by email Literature Review of Diabetes Type 2 trials Research Report on Diabetes Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD Dapagliflozin (DAPA), Placebo - Chronic Kidney Diseases, Diabetes Type 2 | Phase 3 | Not yet recruiting | Assiut University | 210 | 2025-03-01 | 2025-02-11 |
| Canagliflozin Targeting Vascular Inflammation Canagliflozin, Placebo - Diabetes Type 2, Coronary Artery Disease | Phase 2 / Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 24 | 2024-11-15 | 2026-05-06 |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Retatrutide, Placebo - Diabetes Type 2 | Phase 3 | Completed | Eli Lilly and Company | 537 | 2024-04-10 | 2026-03-05 |
| Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation DIAB-PHC1, Metformin - Diabetes Type 2, Diabetes Mellitus, Experimental | Phase 3 | Active not recruiting | Hamdard University | 500 | 2024-03-09 | 2025-12-12 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes Tirzepatide, Placebo - Diabetes Type 2, Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 257 | 2023-02-05 | 2025-08-08 |
| Janagliflozin Treat T2DM Monotherapy Janagliflozin 25mg, Janagliflozin 50mg, Placebo/Janagliflozin - Diabetes Type 2 | Phase 3 | Unknown | Sihuan Pharmaceutical Holdings Group Ltd. | 442 | 2019-05-23 | 2020-07-16 |
| The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity. Laparoscopic Sleeve Gastrectomy, Laparoscopic Roux-en-Y Gastric Bypass, Advanced Medical Therapy - Overweight, Diabetes Type 2 | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 76 | 2015-01-01 | 2019-03-01 |
| Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix Enhanced standard care, Intensive lifestyle intervention - Obesity, Diet Therapy | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 123 | 2013-03-28 | 2026-10-08 |
| Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus Exenatide once weekly suspension, Sitagliptin, Placebo - Diabetes Type 2 | Phase 3 | Completed | AstraZeneca | 365 | 2013-02-01 | 2015-08-20 |
| Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss Diet A, Diet B, Physiotherapy - Abdominal Obesity, Cardiovascular Diseases | Phase 2 / Phase 3 | Completed | Lund University | 105 | 2010-08-01 | 2017-06-20 |
| A Study of OPC-262 in Patients With Type 2 Diabetes OPC-262 2.5 mg, OPC-262 5 mg, Placebo - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 255 | 2009-09-01 | 2014-01-08 |
| Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients DMMET-01, Metformin Hydrochloride - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 20 | 2009-03-01 | 2010-05-18 |
| A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin Metformin 1500 mg daily, Metformin + Janufer (Janumet) - Diabetes Type 2 | Phase 3 | Unknown | Meir Medical Center | 1000 | 2008-06-01 | 2012-03-19 |
| Acetyl-L-Carnitine in Type 2 Diabetes acetyl-L-carnitine/statin (simvastatin), placebo - Diabetes Type 2, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 229 | 2008-04-01 | 2013-02-25 |
| Gait and Balance of Diabetes Type 2 Patients Physiotherapy - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | University Hospital, Geneva | 71 | 2007-09-01 | 2010-01-14 |
| Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy N-acetylcysteine - Diabetic Nephropathy, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Shiraz University of Medical Sciences | 60 | 2007-01-01 | 2007-11-12 |
| Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) - Diabetes Type 2 | Phase 3 | Completed | Mannkind Corporation | 677 | 2006-02-01 | 2014-10-16 |
| Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus Technosphere Insulin - Diabetes Type 2 | Phase 3 | Completed | Mannkind Corporation | 2005-11-01 | 2009-10-14 | |
| Dietary Interventions in Type 2 Obese Diabetic Patients in the Community MUFA diet, ADA 2003, Low Glycemic index (LGI) diet - Diabetes Type 2 | Phase 3 | Unknown | Ben-Gurion University of the Negev | 259 | 2004-03-01 | 2007-09-20 |
Diabetes Mellitus, Type 2 (19) · Diabetes Mellitus (3) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Hypertension (2) · Metabolic Diseases (2) · Overweight (2) · Renal Insufficiency, Chronic (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Experimental (1) · Diabetic Nephropathies (1) · Glucose Intolerance (1) · Obesity (1) · Obesity, Abdominal (1)
Nutritional and Metabolic Diseases (19) · Endocrine System Diseases (17) · Glucose Metabolism Disorders (17) · Metabolic Diseases (17) · Diabetes Mellitus (16) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (4) · Body Weight (3) · Nutrition Disorders (3) · Overnutrition (3) · Vascular Diseases (3) · Body Weight Changes (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2)
Metformin (3) · Physical Therapy Modalities (2) · Acetylcarnitine (1) · Acetylcysteine (1) · Canagliflozin (1) · Diet (1) · Exercise (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Insulin Aspart (1) · Simvastatin (1) · Sitagliptin Phosphate (1) · Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination (1) · Tirzepatide (1) · Whole Grains (1) · dapagliflozin (1)
Eli Lilly and Company (2) · Mannkind Corporation (2) · Assiut University (1) · AstraZeneca (1) · Ben-Gurion University of the Negev (1) · Hadassah Medical Organization (1) · Hamdard University (1) · Kyowa Kirin Co., Ltd. (1) · Laboratorios Silanes S.A. de C.V. (1) · Lund University (1) · Mario Negri Institute for Pharmacological Research (1) · Meir Medical Center (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Ottawa Heart Institute Research Corporation (1) · Shiraz University of Medical Sciences (1)
United States (4) · Israel (3) · Mexico (3) · Canada (2) · China (2) · Russia (2) · Argentina (1) · Brazil (1) · Chile (1) · India (1) · Iran (1) · Italy (1) · Japan (1) · Pakistan (1) · Poland (1)
Drora Fraser, PhD (1) · Joel Zinger, MD (1) · Kaatsuhisa Saito (1) · Kevin Boczar, MD (1) · Lara E Allet, MPtSc (1) · Mai Mostafa, MD (1) · Mary A Hoskin, R.D. (1) · Mehboob Alam, PhD (1) · Peter Ohman (1) · Piero Ruggenenti, MD (1) · Robert Baughman, PhD (1)
PMID 17327309, PMID 18201203, PMID 18579384, PMID 19138520, PMID 19900232, PMID 19921145, PMID 20151996, PMID 20609970, PMID 21999640, PMID 26708836, PMID 28205322, PMID 30230252, PMID 32306296, PMID 33238176, PMID 38017482, PMID 38639002, PMID 40839263, PMID 41029405, PMID 41039470, PMID 41167231, PMID 42250575